Gene Therapy of Cancer

ISBN-13: 9780306460272 / Angielski / Twarda / 1998 / 568 str.

Peter Walden; Uwe Trefzer; Wolfram Sterry

Opis

The book provides a comprehensive overview of the current state, and the new concepts for the future directions of modern cancer therapy. Bringing together all the relevant aspects from basic and applied science, and the clinical experiences of this new direction in medicine, it is an up-to-date summary of the activities in the field and will be the basis for evaluating future progress in this area.

Spis treści

Tumor Biology.- 1. Expression Genetics in Cancer Research, Prognosis, and Therapy.- 2. Patterns of Chromosomal Imbalances in Carcinomas of the Respiratory Tract.- 3. Inhibition of Tumorigenesis in a Murine B-Cell Lymphoma Transplant Model by c-Myc Complementary Oligonucleotides.- 4. Telomerase Inhibition by Induced Expression of Antisense RNA.- 5. Ex Vivo and in Vivo IGF-I Antisense RNA Strategies for Treatment of Cancer in Humans.- 6. Use of the IGF-I Antisense Strategy in the Treatment of the Hepatocarcinoma.- 7. Functional Involvement of CD44, a Family of Cell Adhesion Molecules, in Immune Responses, Tumour Progression and Haematopoiesis.- 8. The Influence of CD44 Splice Variants to the Outcome of Patients with Oral Squamous Cell Carcinoma.- 9. Control of Tumor Growth via Inhibition of Tumor Angiogenesis.- 10. Expression of Collagenase-3 (MMP-13) by Tumor Cells in Squamous Cell Carcinomas of the Head and Neck.- 11. High Level Expression of Tissue Inhibitors of Metalloproteinases-1,-2 and -3 in Melanoma Cells Achieved by Adenovirus Mediated Gene Transfer.- 12. Tissue Inhibitor of Metalloproteinase Expression: A Target for Gene Therapy in Renal Cell Carcinoma.- 13. In Vivo Tumor Suppressor Effect of Retrovirus-Mediated Gene Transfer of the Adenovirus E1a Gene.- 14. Antitumor Effect of E1B Defective Adenoviruses in Human Malignant Cells.- 15. Inhibition of Human Pancreatic Cancer Growth by the Adenovirus-Mediated Introduction of a Novel Growth Suppressing Gene, tob, in Vitro.- Chemogene Therapy.- 16. Intratumoral Injection of Encapsulated Cells Producing an Oxazaphosphorine Activating Cytochrome P450 for Targeted Chemotherapy.- 17. Sensitisation of Human Ovarian Cancer Cells to Killing by the Prodrug CB1954 Following Retroviral or Adenoviral Transfer of the E. coli Nitroreductase Gene.- 18. HSV-1 Thymidine Kinase Gene Therapy for Peritoneal Carcinomatosis.- 19. Characteristics of Cytosine Deaminase-5-Fluorocytosine System: Enhancement of Radiation Cytotoxicity and Bystander Effect.- 20. Potentiation of the Bystander Effect by Immunization Combined with Suicide Gene Therapy.- 21. Another Mechanism Causing the Bystander Effect Besides the Gap Junction’s Role during the Glioma Gene Therapy with HSV-TK/GCV System.- 22. In Vivo Evaluation of a Drug-Inducible Vector System for the Combined Gene- and Chemotherapy of Cancer.- 23. IL-2 Gene Transfer for Chemosensitization of Multidrug-Resistant Human Colon Carcinoma Cells.- 24. Cytotoxic Effect of Binar Cisplatin Immunoconjugate.- 25. Dietary Indole Derivatives Induce Apoptosis in Human Breast Cancer Cells.- Tumor Immunology.- 26. Overcoming T Cell Ignorance by Providing Costimulation: Implications for the Immune Response against Cancer.- 27. Immune Cells in the Tumor Microenvironment: Mechanisms Responsible for Functional and Signaling Defects.- 28. Dendritic Cells Prevent CD95 Mediated T Lymphocyte Death through Costimulatory Signals.- 29. Interleukin-10 Inhibits the Immune Stimulatory Potential of Melanoma Cells Retrovirally Transduced with Human B7.1 or B7.2.- 30. Immunosuppressive Cells in Bone Marrow of Patients with Stomach Cancer.- 31. Induction of Antigen-Specific T Cells by Allogeneic CD80 Transfected Human Carcinoma Cells.- 32. IL-12-Activated NK Cells Recognize B7 Costimulatory Molecules on Tumor Cells and Autologous Dendritic Cells.- 33. Effects of Altered Antigen Processing on T-Cell Responses toward Murine T-Lymphomas.- 34. Cancer Gene Therapy with a Heat Shock Protein Gene.- 35. Heat Shock Protein (HSP72) Surface Expression Enhances the Lysis of a Human Renal Cell Carcinoma by IL-2 Stimulated NK Cells.- 36. Identification of Epitopes for CTCL-Specific Cytotoxic T Lymphocytes.- 37. Effects of Altered Antigen Processing on H-2Dk Mediated NK Inhibition in a Murine T Lymphoma Model.- 38. Recognition of Melanoma-Associated Peptides by Peripheral Blood Mononuclear Cells of Ocular Melanoma Patients.- 39. Detection of Micrometastasis in 31 Patients with Breast Cancer by RT-PCR and Immunomagnetic Separation (ISM) Techniques.- Immunogene Therapy.- 40. Human Tumor Immunotherapy: New Opportunities as Well as New Challenges.- 41. Modification of Cancer Vaccines by Virus Infection and Attachment of Bispecific Antibodies: An Effective Alternative to Somatic Gene Therapy.- 42. Immunotherapy of Established Tumor with MHC Class II and B7.1 Cell-Based Tumor Vaccines.- 43. Retroviral B7.1 Gene Transfer in Cancer Cells Protects Cytotoxic T Cells from Deletion by “Veto” Apoptosis.- 44. Hybrid Cell Vaccination in Cancer Immunotherapy: Recruitment and Activation of T Cell Help for Induction of Anti Tumour Cytotoxic T Cells.- 45. Treatment of Hepatocellular Carcinoma with the Cellular Tumor Vaccines Generated by in Vitro Modification of Tumor Cells with Non Gene Transfer Approaches.- 46. DNA Vaccines Targeting Dendritic Cells for the Immunotherapy of Cancer.- 47. A DNA Vaccine against Malignant Melanoma Coexpressing Antigen and Cytokine.- 48. DNA Immunization in Mice against Virus-Induced Tumor Antigens.- 49. IL-4 Gene Transfer for the Treatment of Experimental Gliomas.- 50. Strategies to Elicit Anti-Idiotypic Immune Response in B-Lymphoma Patients: Peptide and Genetic Immunization.- 51. Autologous Fibroblasts as Potential Vehicle for Regional Ovarian Cancer Gene Therapy.- 52. Adenovirus-Mediated ex Vivo Immunogene and in Vivo Combination Gene Therapy Strategies Induce a Systemic Anti-Tumor Immune Defense in the Mouse B16 Melanoma Model.- 53. Stable Expression of a Retrovirally Transferred Adhesion Molecule in a Human Tumor-Specific CTL Clone: Perspectives for the ex Vivo Manipulation of Effector Cells Used in Adoptive Immunotherapy.- 54. ?-Interferon Gene Transfer as a Therapeutic Strategy for Ovarian Cancer.- 55. Enhancement of Anti-Tumor Immunity by Injection of Fibroblasts Genetically Engineered to Produce IL-12 and to Express CD70.- 56. Sensitization of Human Cells to Lysis by Human Complement as an Approach for Cancer Gene Therapy.- Gene Technology and Gene Targeting.- 57. Targeted Adenoviral Vectors for Cancer Gene Therapy.- 58. High-Efficiency Retroviral Vector-Mediated Gene Transfer into Human T Lymphocytes.- 59. Disabled Infectious Single Cycle (DISC) Herpes Simplex Virus as a Vector for Immunotherapy of Cancer.- 60. Gene Therapy for Familial Adenomatous Polyposis: Prolonged Expression of the Adenomatous Polyposis Coli Gene after Lipofection into Mouse Colon in Vivo.- 61. A Chimeric Fusion Protein of Cytochrome CYP4B1 and Green Fluorescent Protein for Detection of Pro-Drug Activating Gene Delivery and for Gene Therapy in Malignant Glioma.- 62. Toward Targeted Killing of Tumor-Specific Antigen-Producing Cancer Cells by Retrovirus Displaying a Single Chain Variable Fragment Antibody.- 63. A Tool for Enhancing Site-Specific Gene Integration in Mammalian Cells.- 64. Viral Particles with Heterologous Binding Motifs: An Approach to Specifically Alter the Tropism of the B-Lymphotropic Papovavirus.- 65. Efficient Retroviral Infection of Human Cells Utilising an Adenoviral Vector Expressing the Ecotropic Receptor.- 66. Monoclonal Antibody 138H11 against Gamma-Glutamyltransferase Provides a Possible Tool for Targeting Calicheamicin ? to Renal Cell Carcinomas.- 67. Cell Cycle Regulated Promoters for the Targeting of Tumor Endothelium.- 68. Development of a Double-Copy Bicistronic Retroviral Vector for Human Gene Therapy.- 69. Gene-Modified Dendritic Cells by Receptor-Mediated Transfection.- 70. Simple and Fast Microscale Procedure for Transfection and Quantification of Reporter Gene Expression in Eukaryotic Cells.- 71. A Novel Series of Serum-Resistant Lipoaminoacid Compounds for Cellular Delivery of Plasmid DNA.- 72. Comparison of Antisense Vectors and Antisense Oligonucleotides Delivered by Means of the New Cationic Lipids Unifectin and Maxifectin.- 73. Fast-Sorting System for Cells with High-Copy-Number Expression Vectors and Its Use for the Modulation of CML Cells.- 74. Plasmid DNA for Clinical Phase I and II Studies: Large-Scale cGMP Manufacturing and Quality Assurance.- 75. Large Scale Purification of Plasmid DNA for Use in Gene Therapy.- Clinical Trials.- 76. Gene Marking and Gene Therapy in Multiple Myeloma.- 77. p53 and Gene Therapy for Hepatocellular Carcinoma.- 78. Gene Therapy for Malignant Glioma Patients.- 79. Immunization of Metastatic Breast Cancer Patients with CD80-Modified Breast Cancer Cells and GM-CSF.- 80. A Phase I Trial with a Hybrid Cell Vaccine in Patients with Metastatic Melanoma.- 81. Gene Therapy with AdV-IL2 (TG 1021) in Unresectable Digestive Adenocarcinoma: Phase I–II Study, First Inclusions.- 82. Gene Therapy with Cytokine-Transfected Xenogeneic Cells in Metastatic Tumors.- 83. Application of Gene Transfer in Cancer Immunotherapy: From Experimental Data to Clinical Protocols.- 84. Active Immunization of Metastatic Melanoma Patients with IL-2 or IL-4 Gene Transfected, Allogeneic Melanoma Cells.- 85. Preparation for a Phase I/II Study Using Autologous Gene Modified T Lymphocytes for Treatment of Metastatic Renal Cancer Patients.- 86. Immunogene Therapy of Human Melanoma: Phase I/II Clinical Trial.